First, as a single‐patient report, findings cannot be generalized to broader KRAS G12D‐mutated PDAC populations—individual variability in tumor biology, co‐morbidities, and prior treatments may uniquely drive responses or adverse events. Here, KRAS is linked to neoplasm.